During the last decades, a series of important drug products have been developed by which drugs are administered by inhalation to the lungs or to the nasal cavity.

The interest in the field is growing with the aim to enable pharmacological treatment of a broader spectrum of diseases by inhalation. There is a need to match these opportunities with improved inhalation drug delivery technologies and in this meeting, the focus is on one critical aspect in this context, i.e. excipients for inhalation medicines.